Selecta Biosciences and Sanofi to collaborate on allergy vaccines
Sanofi will use Selecta's proprietary synthetic vaccine particle technology to develop highly targeted immunotherapies against life-threatening allergens.
Selecta Biosciences has announced a new collaboration with Sanofi which will see the two companies team up to discover new immunotherapies for serious allergies.
Under the terms of the global agreement, Sanofi will have an exclusive licence to develop a highly targeted, antigen-specific immunotherapy against a life-threatening food allergen, based on Selecta's proprietary Synthetic Vaccine Particle (SVP) platform.
Sanofi will also have an option to develop two additional candidate immunotherapies for allergies to a specific food or aeroallergen.
Dr Werner Cautreels, president and chief executive officer of Selecta, said he was "very pleased" by Sanofi's interest in the clinical-stage biopharmaceutical company's immunotherapy platform.
"In allergies, as well as autoimmune diseases, organ transplantation and protein replacement therapies, there is a lack of specific, effective and safe treatments to prevent undesired immune reactions," he observed.
"Our approach addresses the underlying causes of these diseases and thereby makes advances beyond today's symptomatic treatments and allergen avoidance strategies."
Selecta's technology enables researchers to engineer nanoparticles that produce immune tolerance for therapeutic and prophylactic applications.
The company will be eligible for pre-clinical, clinical, regulatory and sales milestones amounting to $300 million per allergen indication, as well as double-digit tiered royalties on any product sales resulting from the collaboration.
Related News
-
News CPHI Online Trend Report – 2025 Pharma Packaging Prospects
The pharmaceutical packaging market has seen marked shifts in innovations, priorities, and focus over the last few years. With the rise of hit drugs like GLP-1 agonists and biologics requiring specialised packaging considerations, the strain of meeting... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance